Glenn Cross CEO, AusBiotech 


An invitation from Glenn Cross, CEO, AusBiotech

I warmly welcome you to join us at the Adelaide Convention Centre in South Australia for AusBiotech 2017, Australia’s national life science conference.

The annual AusBiotech conference has brought together Australian and international biotech leaders and stakeholders for more than three decades, creating a forum to reflect on the sector’s achievements and exchange ideas to further advance the sector’s standing both nationally and globally. 

The conference is hosted by AusBiotech, Australia’s national industry body representing the life sciences. AusBiotech is a well-connected connected network of over 3,000 members in the life sciences industry, which includes bio-therapeutics, medical technology (devices and diagnostics), food technology, industrial and agricultural biotechnology sectors. Biotechnology continues to be front and centre of Australia’s post-mining boom economic transition and has been a pivotal contributor to Australia’s economy since it emerged over three decades ago.

We are proud to say that the Australian biotechnology industry is flourishing, consisting of an estimated 900 biotechnology companies (400 therapeutics and diagnostics and 500 medical technology companies) and employing more than 45,000 Australians. It is delivering life-saving and life-changing therapeutics to the Australian population and is attracting record-breaking deal flow. The sector’s quality is recognised globally, with biotechnology innovation ranked among the top five for the third consecutive year (Scientific American Worldview Scorecard 2016). As we look ahead to the next three decades, the vital impact of biotechnology on Australia’s social fabric and economy is only anticipated to grow.  

AusBiotech is dedicated to consolidating this growth, and our 2017 conference will once again present issues critical to industry. Global biotech trends, breakthroughs, challenges and success stories will feature prominently on the program. Panel discussions and key themes will cover regulation and reimbursement, research translational strategies, new markets, business development and capital access, emerging technologies, clinical trials and commercisalisation.

To complement the focus on industry and research collaboration, the 2017 program will include specialised streams presenting cutting-edge research in the Australian life sciences. These streams will run in tandem with the traditional industry-focussed sessions, embodying AusBiotech’s plan to draw together the entire life sciences ecosystem, bridge the gap between academia and industry, and foster collaboration across the entire value chain.

AusBiotech’s business matching program AusPartnering will be key to facilitating collaboration and partnership opportunities at the conference. AusPartnering is a mobile app that assists delegates in streamlining their meeting schedules, helping them make the most of the largest annual life sciences conference in Australia.

I invite you to join us in Adelaide for AusBiotech 2017 and encourage you to explore all Australia’s life science industry has to offer.